In addition to an explanation of digital manufacturing, this paper covers how it can improve the productivity and robustness of existing processes and facilities. Gain and understanding of digital biomanufacturing for upstream and downstream processes as well as the technologies that support digital manufacturing of biologics.
Advances in bioprocess monitoring and analytics, as well as in bioinformatics and computational biology, are changing the way we look at the bioproduction process. This poster explains the drivers of the digital biomanufacturing revolution and how they are steering us towards science-based increased plantwide efficiency, quality, adaptability, and profitability.
Having a sound logistics strategy is critical to ensuring this living drug is delivered to the right patient at the right time, location, and temperature is essential to patient safety and product effectiveness.This paper will walk through key considerations for developing a successful logistics strategy for the management of cell-based material.
The emulsion system created when forming microparticle can quickly become complex. Following are critical factors to consider when beginning work with microparticle formulation for a large protein molecule.
An individual that knows the product and processes from start to finish having performed the tasks at each stage gives the client reassurance and the CMO retains a valuable employee by avoiding burnout or loss of focus.
Microbiological contamination is at the top of the CDMO threat list. A CDMO needs to have clearly defined procedures and allow client access to data.
Joe Principe, Vice President of Strategic Partnerships, Patheon, discusses the new set of “must-haves” that are emerging from the increased need for flexibility in outsourced manufacturing partnerships.
Single-use technologies are being seen as the solution to flexibly and cost-effectively address many of the challenges around creating biologics manufacturing capacity.
Pharmaceutical manufacturer and developer, Penn Pharma, has confirmed that its new contained manufacturing facility for producing highly potent products is on track for opening Q1 2013 at an exclusive event held at the British Embassy, Madrid during ICSE.
With nearly 30 years’ experience in supporting all compendial microbiological testing, Nitto Avecia Pharma Services has the in-depth experience, established quality systems, and expertise to best support your product life cycle at any stage.
Nitto Avecia Pharma Services has in-depth experience with a wide range of drug delivery device technologies to offer your programs comprehensive technical support.
Nitto Avecia Pharma Services is a premier contract development and manufacturing organization offering a comprehensive range of cGMP services including formulation development, parenteral manufacturing, and a complete package of CMC analytical services for small to large molecules and nearly all dosage forms